-
Healthcare Resource Utilization and Costs Among Various Disease States in Adults With Hepatitis Delta Virus in Inpatient and Outpatient Settings in the United States
Sep 9, 2025, 16:22 PM -
Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway
Sep 9, 2025, 16:22 PM -
European and US Drug Shortages: A Critical Analysis of Key Trends and Causes
Sep 9, 2025, 16:22 PM -
A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States
Sep 9, 2025, 16:22 PM -
Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data
Sep 9, 2025, 16:22 PM -
The Value of Medical Spending in China, 1991-2019
Sep 9, 2025, 16:22 PM -
Exploring the Healthcare Resource Utilization (HCRU) Associated With Chorea in Patients With Huntington's Disease (HD): A Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM -
Relationship Between Cost-Effectiveness Threshold and Drug Reimbursement in Spain, Italy, and France
Sep 9, 2025, 16:22 PM -
Bridging the Regulatory-Payer Evidence Gap: A Case Study With Six Minute Walk Distance and Mortality
Sep 9, 2025, 16:22 PM -
Psychometric Validation Of The North Star Assessment For Limb-Girdle Type Muscular Dystrophies (NSAD) In Limb-Girdle Muscular Dystrophy Sarcoglycanopathies (LGMD 2C/2D/2E) Using Baseline JOURNEY Data...
Sep 9, 2025, 16:22 PM -
A Comparison of Treatment Costs for CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative HR+/HER2-: Early Breast Cancer (EBC) in Sweden
Sep 9, 2025, 16:22 PM -
Single-Agent vs. Multi-Agent RAG for Health Economic Model Replication: A Comparative Evaluation
Sep 9, 2025, 16:22 PM -
Predicting SMC Appraisal Outcomes Using Machine Learning: A Model to Support Early Market Access Strategy
Sep 9, 2025, 16:22 PM -
Balancing Fit and Accuracy: Evaluating Survival Model Projections With Immature Data in Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria
Sep 9, 2025, 16:22 PM -
Comprehensive Uncertainty Assessment in Economic Evaluations of AI-Based Health Technologies: Pitfalls and Recommendations
Sep 9, 2025, 16:22 PM -
The PHEBUS Study: A Retrospective Analysis of the Burden of Pneumococcal Infections in the Pediatric Population Using the French Hospital Discharge Database (PMSI)
Sep 9, 2025, 16:22 PM -
The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies
Sep 9, 2025, 16:22 PM -
From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany
Sep 9, 2025, 16:22 PM -
Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection
Sep 9, 2025, 16:22 PM
